易布鲁替尼剂量调整对一线CLL/SLL中TTNT的影响:使用目标试验仿真实验分析
Nilanjan Ghosh1, Ruibin Wang2, Zaina P Qureshi2
1Atrium Health Levine Cancer Institute, Wake Forest School of Medicine, Charlotte, NC.
Blood neoplasia
|June 2, 2025
概括
针对慢性淋巴细胞白血病 (CLL) /小淋巴细胞淋巴瘤 (SLL) 的易灵剂量,并没有增加需要后续治疗的风险. 这支持使用剂量调整来维持长期疗效和管理不良事件.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 药理学 药理学 是一个学科.
背景情况:
- 易布鲁替尼是慢性淋巴细胞白血病 (CLL) /小淋巴细胞淋巴瘤 (SLL) 的标准一线 (1L) 治疗方法.
- 调整ibrutinib的剂量可以减轻不良事件,同时保持长期的疗效.
研究的目的:
- 为了比较CLL/SLL患者开始服用420毫克/天的1L易布鲁替尼的时间到下一次治疗.
- 评估剂量调整 (DA) 与维持全剂量对治疗结果的影响.
主要方法:
- 针对两个美国数据库 (Komodo 索赔和 Acentrus EMR) 使用了目标试验仿真方法.
- 分析了开始服用1L单剂IBRUTINIB420 mg/d的患者.
- 随访对两个治疗策略手臂都有贡献,直到偏差.
主要成果:
- 18.0% (Komodo) 和19.6% (Acentrus) 的患者接受了剂量调整.
- 在任何数据库中,剂量调整都与需要下一次治疗的风险增加无关.
- 调整后的危险比率 (95% CI) 为科莫多的0.95 (0.80-1.14) 和阿森特鲁斯的1.14 (0.80-1.62).
结论:
- 易布鲁替尼的灵活剂量在管理不良事件方面似乎是有效的.
- 剂量调整使患者能够持续接受1L治疗,从而可能达到最佳的治疗效果.
相关概念视频
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K